Cori, a partner in our Life Sciences Health Industry Group, focuses her practice on FDA regulatory issues for the food, drug, medical device and cosmetic industries across the supply chain, including companies investing in these industries. Cori has regulatory, transactional, and investigational expertise. She works with clients including medical device manufacturers, pharmaceutical companies, food manufacturers and grocery chains, cosmetic and other CPG retailers, health care PE firms, hospitals, academic medical centers, physicians, and other health care providers.
Cori advises her clients on food and drug law issues, including labeling analysis, FSMA implementation, and food safety issues; clinical research considerations; and corporate compliance concerns. She assists clients during FDA inspections, in responding to FDA 483s and Warning Letters, and with recalls of products. Cori assists companies with regulatory due diligence and deal document drafting during M&A transactions. Her practice includes the representation of clients during internal investigations and self-disclosures. She also represents large corporations in investigations by the US Department of Justice, the US Food and Drug Administration, and other federal and state agencies.
With the passage of the 2018 Federal Farm Bill, Cori has been advising clients about the FDA, USDA, and state law considerations surrounding the use of industrial hemp and other Cannabis derivatives in cosmetics, foods, beverages, and dietary supplements.
Prior to joining, Cori served as a judicial law clerk to Judge Clayton Greene, Jr. on the Court of Appeals of Maryland.
